Merck (NYSE: MRK) spinoff Organon (NYSE: OGN) has completed its acquisition of Alydia Health. Founded in 2010 and based in Menlo Park, California, Alydia is a Women’s Healthcare medical device firm that centers on the prevention of maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding.
Postpartum hemorrhage is one of the most common complications of birth, requiring pharmacologic treatment in up to 10% of mothers and potentially resulting in an emergency intervention such as a hysterectomy and/or blood transfusions. Organon bought Alydia for $240 million.
The FDA has approved Biogen’s (NASDAQ: BIIB) Aduhelm (aducanumab) for the treatment of Alzheimer’s disease, giving patients and medical professionals a desperately needed treatment option of which there are very few. Biogen developed the drug in collaboration with Tokyo, Japan-based Eisai, Co. (OTCMKTS: ESALY).
It has been almost 20 years since the last new Alzheimer’s therapy was approved. There are approximately 6 million persons diagnosed with Alzheimer’s disease in the United States.
HCA Healthcare (NYSE: HCA) and Google (Alphabet-Google NASDAQ: GOOGL) have entered into a deal involving advanced data analytics improving patient care and cost outcomes.
Nashville-based HCA wants to learn more about its patient care performance and how to improve it based on analyzing data from patient records. HCA is one of the largest healthcare provider organizations in the United States.
Founded in 1969, HCA operates 184 hospitals and roughly 2,000 other point-of-care patient service facilities, including various physician practices, surgery centers, and urgent care practices located in 21 states plus the UK.
The sheer scope and size…
Walgreens (NASDAQ: WBA) has shared the encouraging results of an online survey they conducted designed to model the national outlook of those patients receiving a COVID-19 vaccination.
The poll was conducted between April 19 to April 21, 2021, and based on data from:
Walgreens has been administering an array of immunizations at…
Terms of the deal have not been revealed yet but Walmart (NYSE: WMT) has disclosed it is acquiring telehealth innovator MeMD. Founded in 2010, MeMD is a recognized leader in telehealth services nationwide.
Thermo Fisher Scientific (NYSE: TMO) has announced plans to acquire PPD (NASDAQ: PPD) for about $17.4 billion plus the assumption of PPD’s debt which stands around $3.5 billion.
The combination of the two companies pairs two global giants in healthcare diagnostics, medical research and clinical services. Thermo Fisher Scientific is an established leader in diagnostic and medical equipment technology while PPD is one of the largest contract research organizations (CROs) in the world.
Paris-based financial services and insurance giant AXA (OTCMKTS: AXAHY) has selected enterprise technology leader Microsoft (NASDAQ: MSFT) as its partner to build a full-strength telehealth program for its clients and their members.
AXA is one of the largest health insurers in the world. Its plans provide medical coverage to more than 105 consumers and patients in 57 countries. AXA generated about $117.5 billion in sales during 2020.
AXA has no small plans for its telehealth initiative. …
Google, a business unit of Alphabet (NASDAQ: GOOGL) has introduced a new generation of Nest Hub technology that will help its users monitor the quality of their restfulness. The new Nest Hub combines several ambient sensory technologies to provide composite insights to user sleep patterns with its opt-in Sleep Sensing program.
Google is addressing an important underlying healthcare issue as the Centers for Disease Control and Prevention estimates about 70 million people in the United States do not get enough sleep.
The new Nest Hub Sleep Sensing application monitors and compiles data from several human rest and…
Global pharmaceutical giant Pfizer (NYSE: PFE) is evaluating antiviral product pipeline candidates to treat COVID-19 via oral administration as well as IV therapy.
The promising new oral drug candidate, designated as PF-07321332, is being evaluated in a Phase 1, randomized, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study to evaluate its safety, tolerability, and pharmacokinetics in healthy adult patients.
The experimental compound is classified as a protease inhibitor. Protease inhibitors prevent viruses from multiplying by selectively binding to viral proteases and blocking the proteolytic cleavage of protein precursors that are required for viruses to replicate.
Grand Rounds and Doctor On Demand have announced plans to merge and form a larger, more competitive enterprise as the telehealth wave sweeps across the United States and global markets. The market valuation of the combined companies is reportedly over $2 billion.
The new organization will have about 1,500 workers as Grand Rounds employs more than 600 workers and Doctor On Demand has over 900 employees. Grand Rounds, founded in 2012 and Doctor On Demand, started in 2013, are both headquartered in San Francisco, California and privately held.
Grand Rounds will be the primary corporate enterprise once…
Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/